However, the SGLT2i treated cohort were less likely to develop heart failure (RR 0.44 [95% CI 0.23, 0.83] p =0.0092), CKD (RR 0.49 [95% CI 0.28, 0.86] p =0.0118) and be hospitalised for any cause (RR 0.59 [95% CI 0.46, 0.76] p 0.0001) when compared with the GLP-1 RA treated cohort
Titrates to 1.0 mg over ~13 weeks
doi: 10.1016/j.jdiacomp.2018.05.018
Weight loss varies, but Ozempic typically leads to more significant results, while metformin offers modest support
Hazen, M.D., Ph.D., senior author of the study and section head of Preventive Cardiology & Rehabilitation at the Cleveland Clinic
Examples: Using Ozempic (semaglutide) for weight loss is off-label Zepbound is the FDA-approved version specifically labeled for obesity Why this matters: Off-label prescribing can be appropriate, but it may affect insurance coverage and requires careful follow-up and monitoring